A New Poly(ADP-Ribose) Polymerase Inhibitor, FR261529 [2-(4-Chlorophenyl)-5-quinoxalinecarboxamide], Ameliorates Methamphetamine-Induced Dopaminergic Neurotoxicity in Mice
- 1 September 2004
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 310 (3) , 1114-1124
- https://doi.org/10.1124/jpet.104.068932
Abstract
Methamphetamine (METH) administration in mice, results in a chronic dopamine (DA) depletion associated with nerve terminal damage, with DA oxidation and generation of reactive oxygen species (ROS) primarily mediating this neurotoxicity. The oxidative stress induced by METH putatively activates nuclear enzyme poly(ADP-ribose) polymerase (PARP), with excessive PARP activation eventually leading to cell death. In this study, we show that prevention of PARP activation by treatment with FR261529 [2-(4-chlorophenyl)-5-quinoxalinecarboxamide], the compound that was recently identified as a novel PARP inhibitor (IC50 for PARP-1 = 33 nM, IC50 for PARP-2 = 7 nM), protects against both ROS-induced cells injury in vitro and METH-induced dopaminergic neuronal damage in an in vivo Parkinson's disease (PD) model. In PC12 cells, exposure of hydrogen peroxide or METH markedly induced PARP activation, and treatment with FR261529 (1 μM) significantly reduced PARP activation and attenuated cell death. In the mouse METH model, METH (15 mg/kg × 2 i.p., 2 h apart) intoxication accelerated DA metabolism and oxidation in the striatum, with subsequent cell damage in nigrostriatal dopaminergic neurons after 4 days. Oral administration of FR261529 (10 or 32 mg/kg) attenuated the damage of dopaminergic neurons via marked reduction of PARP activity and not via changes in dopamine metabolism or body temperature. These findings indicate that the neuroprotective effects of a novel PARP inhibitor, FR261529, were accompanied by inhibition of METH-induced PARP activation, suggesting that METH induces nigrostriatal dopaminergic neurodegeneration involving PARP activation and also orally active and brain-penetrable PARP inhibitor FR261529 could be a novel attractive therapeutic candidate for neurodegenerative disorders such as PD.This publication has 42 references indexed in Scilit:
- A Novel and Potent Poly(ADP-Ribose) Polymerase-1 Inhibitor, FR247304 (5-Chloro-2-[3-(4-phenyl-3,6-dihydro-1(2 H)-pyridinyl)propyl]-4(3 H)-quinazolinone), Attenuates Neuronal Damage in in Vitro and in Vivo Models of Cerebral IschemiaThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Neuroprotective Effects of a Novel Poly(ADP-Ribose) Polymerase-1 Inhibitor, 2-{3-[4-(4-Chlorophenyl)-1-piperazinyl] propyl}-4(3 H)-quinazolinone (FR255595), in an in Vitro Model of Cell Death and in Mouse 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Model of Parkinson’s DiseaseThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing FactorScience, 2002
- Pharmacologic Inhibition of Poly(ADP-Ribose) Polymerase Is Neuroprotective Following Traumatic Brain Injury in RatsJournal of Neurotrauma, 2001
- Invited Review Free radicals and the pathobiology of brain dopamine systemsNeurochemistry International, 1998
- Role of Nitric Oxide in Methamphetamine Neurotoxicity: Protection by 7‐Nitroindazole, an Inhibitor of Neuronal Nitric Oxide SynthaseJournal of Neurochemistry, 1996
- NMDA Receptor Activation Produces Concurrent Generation of Nitric Oxide and Reactive Oxygen Species: Implications for Cell DeathJournal of Neurochemistry, 1995
- Rapid Communication: Attenuation of Methamphetamine‐Induced Neurotoxicity in Copper/Zinc Superoxide Dismutase Transgenic MiceJournal of Neurochemistry, 1994
- NMDA-dependent superoxide production and neurotoxicityNature, 1993
- Methamphetamine-induced neuronal damage: A possible role for free radicalsNeuropharmacology, 1989